Fluoxetine in patients with major depressive disorder--a responder analysis.
Fluoxetine is a selective serotonin re-uptake inhibitor and thus being a specific antidepressant has its specific responder. In order to attempt a differential description of fluoxetine responders we collected data of 219 patients with major depressive disorder (MDD; DSM-III R) in an open multicenter (phase IV) study, which were further subclassified. According to the treatment plan, these patients were to be treated with 20 mg fluoxetine daily for a period of five weeks. CGI, HAMD, SDS, undesired side effects, laboratory and physiological variables were recorded at weekly intervals. Predictors for response were searched for by means of discriminatory analysis. The stability of the relations found was verified in two randomized halves of the data. It was found that those patients are probably good responders who at base-line have a high Covi anxiety score, but who according to Raskin score, self-assessment of depression (SDS), and CGI are not particularly severely depressed and show a relatively favorable therapeutic response in the first week of treatment.
Klieser
E
E
Rheinische Landes- und Hochschulklinik Düsseldorf, Psychiatric Hospital of the Heinrich Heine University, Germany.
Lehmann
E
E
Heinrich
K
K
D000293:Adolescent; D000328:Adult; D000368:Aged; D001007:Anxiety; D003866:Depressive Disorder / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D005473:Fluoxetine / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D016032:Randomized Controlled Trials as Topic; D018401:Sample Size; D012647:Self-Assessment
D005473:Fluoxetine